Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Solid Tumors 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Small Cell 1Breast Diseases 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × taxane × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04920747 2021-06-10

TandHER

Centre Hospitalier Universitaire de Besancon

Completed
65 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02187822 2021-02-04

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
15 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡